NEWS & BLOG

Singapore, April 2026 – X-ZELL is proud to announce that its new Cryophore™ multiplex antibody panels have achieved IVDR CE marking, representing an important milestone in bringing multiplex immunostaining into routine cytology. First announced in 2025, the new...

Ljubljana, March 2026 – A newly published peer-reviewed paper from the Department of Cytopathology at the Institute of Oncology Ljubljana (IOL), Slovenia, reports promising preliminary results on the use of multiplex Cryoimmunostaining™ in fine-needle aspiration...

Singapore, March 2026 – X-ZELL is proud to announce the commercial launch of its first line of Cryophore™ multiplex antibody panels. Previewed at the 2025 International Congress of Cytology, the new product line marks an important milestone in the company’s mission to...

Halle (Saale), November 2025 – After breaking new ground last year by featuring Cryoimmunostaining™ in the official scientific programme for the first time, the 2025 Seminar on Clinical Cytology in Pulmonology in Halle (Saale), Germany once again placed...

Ljubljana, October 2025 – New clinical data on multiplex Cryoimmunostaining™ took centre stage at an international science conference in Ljubljana, Slovenia, where digital cytology pioneer X-ZELL featured prominently as part of the RadEx IOR Boost project, an...

Florence , May 2025 – X-ZELL is proud to announce the new Cryophore™ range of standardized multiplex antibody panels, developed in close collaboration with leading experts and WHO guideline authors from Europe and the United States. X-ZELL Founder & CEO, Dr...

Halle, November 2024 — A forward-looking panel discussion on the future of multiplex immunostaining took centre stage at the 2024 Seminar on Clinical Cytology in Pulmonology in Halle, Germany, marking a pivotal moment for Cryoimmunostaining™ and its role in routine...

Leipzig, July 2024 – New research from Germany has shown that X-ZELL technology could dramatically reduce the number of inconclusive cancer diagnoses from minimally invasive sample material. During a lecture given at the 45th European Congress of Cytology (ECC) in...

Leipzig, June 2024 – To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has announced the launch of an international Technology Trial program. X-ZELL Founder & CEO, Dr Sebastian Bhakdi, unveiled the new...

Singapore, March 2024 – X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a platform technology combining next-generation...

Singapore, November 2023 – X-ZELL’s first global conference tour has officially wrapped after the series’ final instalment at the Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Austin, Texas, USA. Aimed at promoting X-ZELL’s Next...

Budapest, October 2023 – New research has shown that X-ZELL Cryoimmunostaining™ is able to facilitate same-day cancer diagnoses from minimally invasive samples in routine clinical practice PD Dr. med. Achim Battmann, MD, PhD, chief pathologist at MVZ Frankfurt, a...